Colorectal cancer (CRC) is a prevalent and deadly disease worldwide. Around 1.9 million new cases and over 903,000 deaths were estimated in 2022. 1 In the United States, it has been projected that by ...

There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic ...

PCS involves extensive surgical effort to achieve optimal debulking, defined as no residual tumor or minimal residual disease. This approach has been associated with improved survival rates when ...

Fig 1.Management of the axilla for patients with clinical T ≤2 cm breast cancer. a Multidisciplinary discussion of adjuvant therapy options should occur prior to surgery when omitting sentinel lymph ...

Axillary staging for breast cancer has been a standard part of initial surgical treatment since 2002 when Fisher et al published the National Surgical Adjuvant Breast and Bowel Project (NSABP) B06, 1 ...

ASCO first published evidence-based clinical practice guidelines on FP in 2006, and published updated guidelines in 2013 5 and 2018. 6 This guideline update provides a comprehensive approach to ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included ...

In the United States, the Controlled Substance Act renders cannabis with >0.3% delta-9-tetrahydrocannabinol (THC) schedule I. This status signifies that cannabis has no accepted medical use and a high ...